Geode Capital Management
IMRX icon

Geode Capital Management’s Immuneering IMRX Stock Holding History

Geode Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.84M Buy
1,370,750
+732,806
+115% +$3.71M ﹤0.01% 2746
2026
Q1 		$3.36M Buy
637,944
+19,870
+3% +$102K ﹤0.01% 2921
2025
Q4 		$4.07M Buy
618,074
+104,409
+20% +$670K ﹤0.01% 2882
2025
Q3 		$3.6M Buy
513,665
+283,390
+123% +$1.47M ﹤0.01% 2940
2025
Q2 		$776K Buy
230,275
+4,458
+2% +$7.64K ﹤0.01% 3414
2025
Q1 		$343K Buy
225,817
+17,430
+8% +$31.7K ﹤0.01% 3677
2024
Q4 		$459K Sell
208,387
-1,254
-0.6% -$2.6K ﹤0.01% 3624
2024
Q3 		$522K Sell
209,641
-12,160
-5% -$17.7K ﹤0.01% 3569
2024
Q2 		$284K Sell
221,801
-240,719
-52% -$396K ﹤0.01% 3786
2024
Q1 		$1.34M Buy
462,520
+18,287
+4% +$102K ﹤0.01% 3254
2023
Q4 		$3.27M Buy
444,233
+11,529
+3% +$76.8K ﹤0.01% 2908
2023
Q3 		$3.32M Buy
432,704
+44,378
+11% +$408K ﹤0.01% 2850
2023
Q2 		$3.94M Buy
388,326
+219,107
+129% +$2.11M ﹤0.01% 2819
2023
Q1 		$1.64M Hold
169,219
– – ﹤0.01% 3114
2022
Q4 		$820K Sell
169,219
-372
-0.2% -$3.29K ﹤0.01% 3448
2022
Q3 		$2.43M Buy
169,591
+94,991
+127% +$754K ﹤0.01% 3021
2022
Q2 		$403K Sell
74,600
-163,816
-69% -$874K ﹤0.01% 3882
2022
Q1 		$1.54M Buy
238,416
+104,601
+78% +$1M ﹤0.01% 3389
2021
Q4 		$2.16M Buy
133,815
+11,496
+9% +$280K ﹤0.01% 3330
2021
Q3 		$3.25M Buy
+122,319
New +$3.29M ﹤0.01% 3152

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Geode Capital Management's IMRX Position: Q2 2026 in Review

Geode Capital Management increased its Immuneering (IMRX) stake by 115% in Q2 2026, buying an estimated $3.71M and bringing the position to 1,370,750 shares worth $6.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2746.

Geode Capital Management first reported a position in IMRX in Q3 2021 and has held it in 20 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Geode Capital Management held 1,370,750 shares of Immuneering worth $6.84M as of Q2 2026.
  • Geode Capital Management bought 732,806 Immuneering shares in Q2 2026, an estimated $3.71M.
  • Immuneering made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2746 holding.
  • Geode Capital Management first reported a position in Immuneering in Q3 2021 and has held it in 20 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.